Testing radiation plus a mix of drugs for breast cancer that has spread to the brain
Original title: Study of Radiotherapy Combined With Cisplatin/Carboplatin, Adebrelimab and Bevacizumab in the Treatment of TNBC-BM.
How far along is this research?
This is a trial that is enrolling or has been updated. It is not a finding yet.
This is a middle-stage test in people to see if it works and is safe.
Status: Recruiting. It is looking for patients now. Talk to your care team about whether it fits you.
The trial team last updated this record on . Always check the trial page for the latest.
The short version
This study tests radiation given along with several drugs for a type of breast cancer that has spread to the brain.
Who this trial is for. This trial is for people with triple-negative breast cancer that has spread to the brain. It tests radiation given with cisplatin or carboplatin, plus adebrelimab and bevacizumab: A drug that acts on the blood vessels a tumor builds. In brain tumors it is used mainly to control symptoms from swelling, and to reduce how much steroid someone needs. See the glossary.
Where it stands. The study wants to learn how well this mix works and how safe it is. The trial has not reported any results yet. The answer is not in.
What this means, and what it doesn't
What it could mean: This trial checks if this mix could help people with this kind of cancer. If you have it, you could ask your care team if this trial might fit you. The trial team decides who can join.
What it doesn't mean: A trial is a test, not a proven treatment. Being in a trial does not mean it will help you. This is not a cure, and no one can promise one.
Source: ClinicalTrials.gov, September 10, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.